New MRD Assessment Data Using clonoSEQ® To Be Presented at 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Read More

Browse our 650+ Publications​

Latest Publications

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma

Smith MR, et al.
Blood
May 2024
Authors and Affiliates
Mitchell R. Smith 1, Opeyemi A. Jegede 2, Peter Martin 3, Brian G. Till 4, Samir S. Parekh 5, David T. Yang 6, Eric D. Hsi 7, Thomas Witzig 7, Sandeep Dave 8, David Scott 9, Curtis Hanson 7, Lale Kostakoglu Shields 10, Nizar Abdel-Samad 11, Carla Casulo 12, Nancy L. Bartlett 13, Paolo F. Caimi 14, Tareq Al Baghdadi 15, Kristie A. Blum 16, Mark D. Romer 17, David J. Inwards 7, Rachel E. Lerner 18, Lynne I. Wagner 19, Richard F. Little 20 , Jonathan W. Friedberg 12, John P. Leonard 3, Brad S. Kahl 13 1. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*, 2. Dana Farber Cancer Institute, Boston, MA; 3. Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; 4. Fred Hutchinson Cancer Center, Seattle, WA; 5. Mount Sinai, New York, NY; 6. University of Wisconsin Carbone Cancer Center, Madison, WI; 7. Mayo Clinic, Rochester, MN; 8. Duke University Medical Center, Durham, NC; 9. BCCA-Vancouver Cancer Centre, Vancouver, BC, Canada; 10. NYU-Langhorne Cancer Center, NY, NY; 11. The Moncton Hospital, Moncton, NB, Canada; 12. University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY; 13. Washington University School of Medicine St. Louis and Siteman Cancer Center, St. Louis, MO; 14. Case Comprehensive Cancer Center, Cleveland, OH; 15. St. Joseph Mercy Hospital, Ann Arbor, MI ; 16. Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH; 17. Good Samaritan Hospital - Dayton, Kettering, OH; 18. Frauenshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN; 19. University of North Carolina at Chapel Hill, Chapel Hill, NC; 20. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

Derman B, et al.
Blood Cancer Journal
May 2024
Authors and Affiliates
Benjamin A. Derman1, Jennifer Cooperrider1, Jacalyn Rosenblatt2, David E. Avigan2, Murtuza Rampurwala1, David Barnidge3, Ajay Major 4, Theodore Karrison5, Ken Jiang1, Aubrianna Ramsland1, Tadeusz Kubicki 1 and Andrzej J. Jakubowiak 1 1Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA. 2Beth Israel Deaconess Medical Center, Boston, MA, USA. 3The Binding Site Group, part of Thermo Fisher, Rochester, MN, USA. 4University of Colorado, Denver, CO, USA. 5Department of Public Health Sciences, University of Chicago, Chicago, IL, USA.

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle celllymphoma: 2-year safety and efficacy analysis

Wang M, et al.
Blood Advances
May 2024
Authors and Affiliates
Michael Wang (The University of Texas M.D. Anderson Cancer Center, United States) Tadeusz Robak (Medical University of Lodz, Poland) Kami Maddocks (The Ohio State University, United States) Tycel Phillips (University of Michigan Comprehensive Cancer Center, United States) Stephen Smith (University of Washington/Seattle Cancer Care Alliance, United States) David Gallinson (Summit Medical Group, United States) Roser Calvo (AstraZeneca, United States) Chuan-Chuan Wun (AstraZeneca, United States) Veerendra Munugalavadla (AstraZeneca, United States) Wojciech Jurczak (Maria Sklodowska-Curie National Research Institute of Oncology, Poland)

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Touzeau C, et al.
Blood
May 2024
Authors and Affiliates
Cyrille Touzeau,1-3 Aurore Perrot,4 Cyrille Hulin,5 Salomon Manier,6 Margaret Macro,7 Marie-Lorraine Chretien,8 Lionel Karlin,9 Martine Escoffre,10 Caroline Jacquet,11 Mourad Tiab,12 Xavier Leleu,13 Herve Avet-Loiseau,4 Alexandra Jobert,14 Lucie Planche,14 Jill Corre,4 and Philippe Moreau1-3 1Service d’hématologie, Centre Hospitalier Universitaire (CHU) Hotel Dieu, Nantes, France; 2Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (CRCI2NA), INSERM, Centre National de la Recherche Scientifique (CNRS), Université d'Angers, Université de Nantes, Nantes, France; 3Site de Recherche Intégrée sur le Cancer (SIRIC) “Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD),” Institut National du Cancer-Direction Générale de l'Offre de Soins (INCA-DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM) 12558, Nantes-Angers, France; 4CHU de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Université de Toulouse, Université Paul Sabatier (UPS), Service d’Hématologie, Toulouse, France; 5Service d’hématologie, Hopital Haut-Léveque, CHU de Bordeaux, Pessac, France; 6Maladies du Sang, CHRU de Lille, Lille, France; 7Service d’hématologie, CHU de Caen, Caen, France; 8Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France; 9Hopital Lyon Sud, Pierre-Bénite, France; 10Service d’hématologie, CHU de Rennes, Rennes, France; 11Service d’hématologie, CHU de Nancy, Vandoeuvre-le` s-Nancy, France; 12Service d’hématologie, Centre Hospitalier Departemental, La Roche sur Yon, France; 13Service d’hématologie, CHU de Poitiers, Poitiers, France; and 14Département de recherche clinique, CHU Hotel Dieu, Nantes, France

French early nationwide idecabtagene vicleucel chimeric antigen receptor T-cell therapy experience in patients with relapsed/refractory multiple myeloma (FENIX): A real-world IFM study from the DESCAR-T registry

Ferment B, et al.
British Journal of Haematology
May 2024
Authors and Affiliates
B. Ferment1,2 J. Lambert3 D. Caillot4,5 I. Lafon4 L. Karlin6 A. Lazareth6 C. Touzeau7 X. Leleu8 N. Moya8 S. Harel1,2 A. Perrot9 P. Bories9 L. Vincent10 S. Lamure11 M. Mohty12 F. Malard12 S. Manier13 I. Yakoub-Agha13 J.-M. Schiano De Colella14 G. Brisou14 A. Talbot1,2 O. Decaux15 R. Houot15 S. Le Gouill16,17 N. Bigot3 T. Facon13 J. Corre9 P. Moreau7 B. Arnulf1,2 1Department of Immuno-Hematology, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 2Inserm U976 HIPI, Team 5: Lymphocyte Development and Lymphoid Disorders, Hôpital Saint Louis, Paris, France 3Biostatistics Department, Hôpital Saint Louis, APHP/Université Paris Cité, Paris, France 4Department of Hematology, Institut de Cancérologie de Bourgogne (ICB), Dijon, France 5Department of Hematology, Dijon University Hospital, Dijon, France 6Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre-Benite, France 7Department of Hematology, Nantes University Hospital, Nantes, France 8Department of Oncology-Haematology and Cellular Therapy, Poitiers University Hospital, Poitiers, France 9Department of Hematology, IUCT Oncopole—Institut Universitaire du Cancer de Toulouse, Toulouse, France 10Department of Hematology, Montpellier University Hospital, Montpellier, France 11Department of Hematology, Centre Léon Bérard, Lyon, France 12Saint-Antoine Hospital, INSERM UMRs 938, Sorbonne University, Paris, France 13Department of Hematology, Lille Regional and University Hospital, Lille, France 14Department of Hematology, Institut Paoli Calmettes, Marseille, France 15Department of Hematology, Rennes University Hospital, Pontchaillou Hospital, Rennes, France 16Université Versailles Saint-Quentin, Versailles, France 17Department of Hematology, Institut Curie, Paris, France

How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL

Muffly L, et al.
Blood
May 2024
Authors and Affiliates
Lori Muffly (Stanford University, United States) Emily Liang (Fred Hutchinson Cancer Center, United States) J. Dolan (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah, United States) Michael Pulsipher (Huntsman Cancer Institute/Intermountain Primary Chlldren's Hospital, Spencer Fox Eccles School of Medicine, University of Utah., United States)

Mass Spectrometry-Based Assessment of M-protein in Peripheral Blood DuringMaintenance Therapy in Multiple Myeloma

Kubicki T, et al.
Blood
May 2024
Authors and Affiliates
Tadeusz Kubicki,1,2 Dominik Dytfeld,2 David Barnidge,3 Dhananjay Sakrikar,3 Anna Przybyłowicz-Chalecka,2 Krzysztof Jamroziak,4 Paweł Robak,5 Jarosław Czyż,6 Agata Tyczyńska,7 Agnieszka Druzd-Sitek,8 Krzysztof Giannopoulos,9 Tomasz Wróbel,10 Adam Nowicki,2 Tomasz Szczepaniak,2 Anna Łojko-Dankowska,2 Magdalena Matuszak,2 Lidia Gil,2 Bartosz Puła,11 Łukasz Szukalski,6 Agnieszka Końska,11 Jan Maciej Zaucha,7 Jan Walewski,8 Damian Mikulski,5 Olga Czabak,12 Tadeusz Robak,5 Ken Jiang, 1 Jennifer H Cooperrider, 1 Andrzej J Jakubowiak,1,* and Benjamin A Derman1,* 1University of Chicago, Chicago, USA; 2 Poznań University of Medical Sciences, Poznan, Poland; 3The Binding Site, part of Thermo Fisher, Rochester, USA; 4 Medical University of Warsaw, Warsaw, Poland; 5Medical University of Łódź, Łódź, Poland; 6 Nicolaus Copernicus University in Toruń Ludwik Rydygier, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland; 7Medical University of Gdańsk, Gdańsk, Poland; 8 Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; 9 Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland; 10 Wrocław Medical University, Wrocław, Poland; 11 Institute of Hematology and Blood Transfusion, Warsaw; 12 Medical University of Lublin, Lublin, Poland

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial

O'Donnell E, et al.
Lancet Haematology
April 2024
Authors and Affiliates
Elizabeth O’Donnell, Clifton Mo, Andrew J Yee, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil Munshi, Shonali Midha, Diana Cirstea, Pavlina Chrysafi, Nora Horick, Paul G Richardson, Noopur Raje Massachusetts General Hospital Cancer Center, Boston, MA, USA (E O’Donnell MD, A J Yee MD, D Cirstea MD, N Horick MS, Prof N Raje MD); Dana-Farber Cancer Institute, Boston, MA, USA (E O’Donnell, C Mo MD, O Nadeem MD, J Laubach MD, Prof N Munshi MD, S Midha MD, Prof P G Richardson MD); Beth Israel Deaconess Medical Center, Boston, MA, USA (J Rosenblatt MD); Mount Auburn Hospital, Cambridge, MA, USA (P Chrysafi MD); Harvard Medical School, Boston, MA, USA (E O’Donnell, C Mo, A J Yee, O Nadeem, J Laubach, J Rosenblatt, N Munshi, Prof S Midha, D Cirstea, P G Richardson, Prof N Raje)

Long-term follow-up of patients with follicular lymphoma using next generation sequencing to detect minimal residual disease

Clinical Lymphoma Myeloma & Leukemia
April 2024
Authors and Affiliates
Ayushi Chauhan2, Catherine Lai4 Frank Kuhr3, Heidi Simmons3, Bruce D. Cheson1 1- Center for Cancer and Blood Disorders, Bethesda, MD; 2- Medical College of Georgia, Augusta, Georgia; 3-Adaptive Biotechnologies, Seattle, WA; 4-University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA
Previous Next

The latest from Adaptive

News Releases